Serena Patricia Koenig, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haiti | 38 | 2023 | 551 | 2.680 |
Why?
|
| Tuberculosis | 13 | 2023 | 2002 | 2.110 |
Why?
|
| HIV Infections | 37 | 2023 | 17128 | 1.950 |
Why?
|
| Anti-HIV Agents | 15 | 2023 | 4490 | 1.680 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2018 | 1894 | 1.460 |
Why?
|
| Anti-Retroviral Agents | 10 | 2020 | 1780 | 1.360 |
Why?
|
| Isoniazid | 3 | 2022 | 283 | 1.210 |
Why?
|
| Antitubercular Agents | 6 | 2022 | 1374 | 0.960 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2019 | 931 | 0.890 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2019 | 2569 | 0.770 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2020 | 2198 | 0.760 |
Why?
|
| Ethionamide | 1 | 2019 | 11 | 0.660 |
Why?
|
| Ethambutol | 1 | 2019 | 59 | 0.650 |
Why?
|
| Pyrazinamide | 1 | 2019 | 60 | 0.640 |
Why?
|
| Fluoroquinolones | 2 | 2019 | 309 | 0.590 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2018 | 832 | 0.510 |
Why?
|
| Earthquakes | 3 | 2017 | 185 | 0.470 |
Why?
|
| Mass Screening | 5 | 2019 | 5419 | 0.460 |
Why?
|
| Peritonitis, Tuberculous | 1 | 2013 | 6 | 0.440 |
Why?
|
| Communicable Disease Control | 3 | 2017 | 844 | 0.430 |
Why?
|
| Government Programs | 1 | 2014 | 280 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 3 | 2016 | 924 | 0.400 |
Why?
|
| Patient Dropouts | 1 | 2013 | 412 | 0.360 |
Why?
|
| Disasters | 2 | 2015 | 518 | 0.340 |
Why?
|
| Health Care Costs | 2 | 2014 | 3255 | 0.340 |
Why?
|
| HIV | 3 | 2020 | 1579 | 0.310 |
Why?
|
| Zidovudine | 1 | 2010 | 624 | 0.310 |
Why?
|
| Standard of Care | 1 | 2011 | 551 | 0.290 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 5317 | 0.290 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3556 | 0.270 |
Why?
|
| Developing Countries | 6 | 2018 | 2876 | 0.260 |
Why?
|
| Cough | 3 | 2019 | 595 | 0.260 |
Why?
|
| Sputum | 3 | 2019 | 502 | 0.260 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2003 | 53 | 0.230 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4359 | 0.210 |
Why?
|
| Adult | 30 | 2023 | 219390 | 0.210 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2019 | 1905 | 0.200 |
Why?
|
| Community Health Services | 2 | 2004 | 653 | 0.200 |
Why?
|
| Latin America | 2 | 2020 | 404 | 0.190 |
Why?
|
| Public Health | 1 | 2014 | 2654 | 0.190 |
Why?
|
| Humans | 51 | 2023 | 759255 | 0.190 |
Why?
|
| Lesotho | 1 | 2020 | 74 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2013 | 2123 | 0.180 |
Why?
|
| Poverty Areas | 2 | 2017 | 264 | 0.180 |
Why?
|
| World Health Organization | 3 | 2017 | 1317 | 0.180 |
Why?
|
| Rural Health Services | 1 | 2004 | 381 | 0.180 |
Why?
|
| Lost to Follow-Up | 2 | 2017 | 124 | 0.180 |
Why?
|
| Cohort Studies | 10 | 2022 | 41247 | 0.160 |
Why?
|
| Africa | 1 | 2020 | 706 | 0.160 |
Why?
|
| Male | 29 | 2019 | 358719 | 0.150 |
Why?
|
| Female | 30 | 2019 | 390240 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 4898 | 0.140 |
Why?
|
| Middle Aged | 18 | 2019 | 219653 | 0.140 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 1395 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 5500 | 0.130 |
Why?
|
| Young Adult | 10 | 2019 | 58483 | 0.130 |
Why?
|
| Caribbean Region | 2 | 2015 | 191 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2019 | 64879 | 0.130 |
Why?
|
| Blood-Borne Pathogens | 1 | 1995 | 52 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 12522 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2020 | 1611 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 585 | 0.120 |
Why?
|
| Medication Adherence | 2 | 2018 | 2161 | 0.120 |
Why?
|
| Circumcision, Male | 1 | 2015 | 149 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 122 | 0.110 |
Why?
|
| HIV Seronegativity | 1 | 2014 | 208 | 0.110 |
Why?
|
| Universal Precautions | 1 | 1993 | 34 | 0.110 |
Why?
|
| Biostatistics | 1 | 2015 | 163 | 0.110 |
Why?
|
| Body Fluids | 1 | 1995 | 319 | 0.110 |
Why?
|
| RNA | 1 | 2023 | 2723 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 1943 | 0.100 |
Why?
|
| Rural Health | 2 | 2004 | 299 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2019 | 80121 | 0.100 |
Why?
|
| Sex Factors | 3 | 2017 | 10518 | 0.100 |
Why?
|
| Omentum | 1 | 2013 | 169 | 0.100 |
Why?
|
| Students, Medical | 2 | 1995 | 1920 | 0.090 |
Why?
|
| Health Resources | 2 | 2010 | 934 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 1342 | 0.090 |
Why?
|
| Directly Observed Therapy | 2 | 2014 | 140 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 3959 | 0.080 |
Why?
|
| Live Birth | 1 | 2013 | 513 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2014 | 955 | 0.080 |
Why?
|
| HIV-1 | 2 | 2019 | 6848 | 0.080 |
Why?
|
| Triage | 1 | 2015 | 982 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6496 | 0.080 |
Why?
|
| Prevalence | 5 | 2019 | 15641 | 0.080 |
Why?
|
| International Cooperation | 1 | 2014 | 1436 | 0.080 |
Why?
|
| Socioeconomic Factors | 5 | 2017 | 7790 | 0.070 |
Why?
|
| Time Factors | 4 | 2017 | 40109 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2019 | 9282 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2015 | 6242 | 0.070 |
Why?
|
| Adolescent | 8 | 2019 | 87560 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2012 | 1516 | 0.070 |
Why?
|
| Health Services Administration | 1 | 2006 | 63 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12152 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 749 | 0.060 |
Why?
|
| Survival Rate | 2 | 2017 | 12800 | 0.060 |
Why?
|
| Cholera | 1 | 2011 | 774 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2011 | 1248 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2011 | 1758 | 0.060 |
Why?
|
| Simian immunodeficiency virus | 3 | 1995 | 805 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 15728 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39216 | 0.050 |
Why?
|
| Incidence | 4 | 2017 | 21336 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2689 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1995 | 1765 | 0.050 |
Why?
|
| Vaccines, Synthetic | 3 | 1995 | 617 | 0.050 |
Why?
|
| Risk Factors | 7 | 2020 | 74167 | 0.050 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 5377 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2010 | 1378 | 0.050 |
Why?
|
| Health Personnel | 1 | 2015 | 3309 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3863 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 4608 | 0.050 |
Why?
|
| Premature Birth | 1 | 2013 | 1765 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 1995 | 4389 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2013 | 5955 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8594 | 0.040 |
Why?
|
| Capreomycin | 1 | 2018 | 14 | 0.040 |
Why?
|
| Amikacin | 1 | 2018 | 48 | 0.040 |
Why?
|
| Kanamycin | 1 | 2018 | 64 | 0.040 |
Why?
|
| Clofazimine | 1 | 2018 | 41 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 559 | 0.040 |
Why?
|
| Brazil | 1 | 2022 | 1211 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2003 | 627 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 123 | 0.040 |
Why?
|
| Viral Vaccines | 2 | 1993 | 597 | 0.040 |
Why?
|
| Comorbidity | 1 | 2012 | 10547 | 0.040 |
Why?
|
| Poverty | 3 | 2004 | 2682 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 54204 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4358 | 0.030 |
Why?
|
| United States | 2 | 2015 | 72237 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2009 | 10185 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2010 | 6368 | 0.030 |
Why?
|
| Rural Population | 2 | 2003 | 2260 | 0.030 |
Why?
|
| Gene Products, gag | 2 | 1995 | 312 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2004 | 2487 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6532 | 0.030 |
Why?
|
| Aged | 4 | 2018 | 168617 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15815 | 0.030 |
Why?
|
| SAIDS Vaccines | 1 | 1995 | 144 | 0.030 |
Why?
|
| BCG Vaccine | 2 | 1995 | 370 | 0.030 |
Why?
|
| Depression | 1 | 2013 | 8026 | 0.030 |
Why?
|
| Protective Clothing | 1 | 1993 | 103 | 0.030 |
Why?
|
| Proteolipids | 1 | 1992 | 113 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26109 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 1155 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 1195 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 2642 | 0.030 |
Why?
|
| Pandemics | 1 | 2012 | 8609 | 0.030 |
Why?
|
| Patient Selection | 1 | 2004 | 4269 | 0.020 |
Why?
|
| Logistic Models | 2 | 2019 | 13309 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 29658 | 0.020 |
Why?
|
| Culture Media | 1 | 2013 | 899 | 0.020 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 1995 | 538 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 998 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 3152 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2003 | 6195 | 0.020 |
Why?
|
| Educational Status | 1 | 2017 | 2511 | 0.020 |
Why?
|
| Developed Countries | 1 | 2012 | 443 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 58867 | 0.020 |
Why?
|
| Survivors | 1 | 2019 | 2356 | 0.020 |
Why?
|
| Clinical Clerkship | 1 | 1995 | 562 | 0.020 |
Why?
|
| Tanzania | 1 | 2013 | 1374 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2017 | 2035 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3699 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2012 | 571 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2004 | 4639 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8469 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 2649 | 0.020 |
Why?
|
| Mental Health | 1 | 2019 | 3195 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 1800 | 0.010 |
Why?
|
| Homosexuality, Male | 1 | 2012 | 1268 | 0.010 |
Why?
|
| Macaca mulatta | 3 | 1995 | 2315 | 0.010 |
Why?
|
| Smoking | 1 | 2019 | 9066 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 2627 | 0.010 |
Why?
|
| Occupations | 1 | 2003 | 513 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 5880 | 0.010 |
Why?
|
| Sexual Partners | 1 | 2003 | 749 | 0.010 |
Why?
|
| Obesity | 1 | 2019 | 12896 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 17629 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1995 | 341 | 0.010 |
Why?
|
| Genes, gag | 1 | 1993 | 56 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 12450 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1388 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1992 | 240 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1992 | 266 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 13456 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 2817 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 20031 | 0.010 |
Why?
|
| Child | 1 | 2017 | 79623 | 0.010 |
Why?
|
| Liposomes | 1 | 1992 | 776 | 0.010 |
Why?
|
| Immunization | 1 | 1993 | 1228 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 4171 | 0.000 |
Why?
|
| Age Factors | 1 | 2003 | 18394 | 0.000 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1993 | 1354 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2003 | 21988 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1993 | 3377 | 0.000 |
Why?
|
| Peptides | 1 | 1993 | 4357 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1995 | 18968 | 0.000 |
Why?
|
| Cell Line | 1 | 1992 | 15636 | 0.000 |
Why?
|
| Animals | 3 | 1995 | 167838 | 0.000 |
Why?
|